Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

NCT03539536 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03539536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03539536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 10, 2018
Completion date
August 31, 2026
Enrollment
270 (actual)
Sites
252

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer